An Update on the Treatment of Pediatric Autoimmune Encephalitis
Authors:
- 17 February 2018
- journal article
- research article
- Published by Springer Nature in Current Treatment Options in Rheumatology
- Vol. 4 (1) , 14-28
Abstract
Purpose of review Autoimmune encephalitis (AE) is an increasingly recognized etiology for neuropsychiatric deficits that are highly responsive to immunotherapy. As a result, rheumatologists are often called upon to help with the diagnosis and treatment of these conditions. The purpose of this review is to provide an update on the pharmacologic treatment of AE. Recent findings To date, there are no prospective randomized placebo-controlled trials to guide treatment recommendations for AE. First-line therapies include corticosteroids, intravenous immunoglobulin, and plasma exchange. Second-line therapies include rituximab and cyclophosphamide (CYC), as well as mycophenolate mofetil and azathioprine. For patients refractory to both first- and second-line therapy, there is emerging evidence for the interleukin-6 (IL-6) inhibitor tocilizumab, the proteasome inhibitor bortezomib, and low-dose IL-2. Early treatment initiation and treatment escalation in patients with refractory disease improve outcomes. Given the delayed time between dosing and treatment effects of second-line agents, continuing first-line treatment until the patients shows improvement is recommended. Summary Although AE can present with dramatic, life-threatening neuropsychiatric deficits, the potential for recovery with prompt treatment is remarkable. First- and second-line therapies for AE lead to clinical improvement in the majority of patients, including full recoveries in many. Early treatment and escalation to second-line therapy in those with refractory disease improves patient outcomes. Novel treatments including IL-6 blockade and proteasome inhibitors have shown promising results in patients with refractory disease.Keywords
Funding Information
- National Human Genome Research Institute (1T32HG008955-01)
This publication has 64 references indexed in Scilit:
- B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodiesArthritis Research & Therapy, 2013
- Paediatric autoimmune encephalopathies: clinical features, laboratory investigations and outcomes in patients with or without antibodies to known central nervous system autoantigensJournal of Neurology, Neurosurgery & Psychiatry, 2012
- Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumabModern Rheumatology, 2012
- Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitisThe Lancet Neurology, 2011
- Cellular and Synaptic Mechanisms of Anti-NMDA Receptor EncephalitisThe Journal of Neuroscience, 2010
- Rituximab specifically depletes short-lived autoreactive plasma cells in a mouse model of inflammatory arthritisProceedings of the National Academy of Sciences, 2010
- Antibodies to the GABAB receptor in limbic encephalitis with seizures: case series and characterisation of the antigenThe Lancet Neurology, 2010
- Clinical applications of intravenous immunoglobulins in neurologyClinical and Experimental Immunology, 2009
- Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodiesThe Lancet Neurology, 2008
- A patient with encephalitis associated with NMDA receptor antibodiesNature Clinical Practice Neurology, 2007